First Tracks Biotherapeutics (TRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, First Tracks Biotherapeutics (TRAX) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($257.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See First Tracks Biotherapeutics balance sheet independence to measure how much of total assets are equity-financed.
First Tracks Biotherapeutics - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how First Tracks Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TRAX long-term investment intensity to see how much of total assets are deployed in long-term investments.
First Tracks Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of First Tracks Biotherapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Electronics Mart India Limited
NSE:EMIL
|
0.167x |
|
ALLIANZ TECHNO.TR.LS-025
F:28X
|
-0.360x |
|
Mayville Engineering Co Inc
NYSE:MEC
|
-0.012x |
|
Dap Gayrimenkul Gelistirme AS
IS:DAPGM
|
0.016x |
|
Wam Global Ltd
AU:WGB
|
0.044x |
|
Zhejiang Dafeng Industrial Co Ltd
SHG:603081
|
0.052x |
|
Rural Funds Group
AU:RFF
|
0.027x |
|
7 Eleven Malaysia Holdings Bhd
KLSE:5250
|
0.179x |
Annual Cash Flow Conversion Efficiency for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual cash flow conversion efficiency of First Tracks Biotherapeutics from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see TRAX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.49 Million | $-142.93 Million | -0.497x | -54.75% |
| 2024-12-31 | $391.60 Million | $-125.81 Million | -0.321x | -41.57% |
| 2023-12-31 | $409.85 Million | $-93.00 Million | -0.227x | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more